CA-CROWN-BIOSCIENCE
Crown Bioscience , a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer , on a bispecific antibody which prevents the onset of metastasis and slows the growth of primary tumors in experimental models of cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220428006002/en/
The study was the result of work by an international consortium, SuppresSTEM which included Crown Bioscience (previously OcellO B.V.) and HUB. Crown Bioscience and HUB led the design of the experiments which were executed using the high content screening platform from Crown Bioscience using HUB Organoids. These studies enabled the discrimination of antibodies that were active against a broad range of mutational profiles and tumor subtypes, with hit validation and mechanism of action studies that enabled selection of optimally performing antibodies. Follow up in vivo studies in matched patient-derived xenograft (PDX) models were also performed by Crown Bioscience.
The work, spanning about five years, involved Crown Bioscience screening a library of hundreds of bispecific antibodies and rescreening of ‘hits’ in a panel of patient-derived colorectal cancer organoids and matching normal organoids, that were developed by HUB and characterized by HUB and other consortium members. Organoids are stem cell-derived mini-organs developed from any patient resection or biopsy tissue that can be grown in the laboratory, which can be applied like conventional cell lines in early drug discovery.
“This is the first study that has used organoids exclusively for cell-based compound screening and characterization, leading to a compound entering clinical trials. This is a truly remarkable achievement that demonstrates the validity and application of HUB Organoids in high throughput screening and oncology drug discovery”, said Leo Price PhD, Senior Vice President In Vitro Oncology at Crown Bioscience.
“This groundbreaking work demonstrates the power and potential of HUB Organoid Technology”, commented Rob Vries PhD, CEO at HUB. “Using organoids, we were able to accelerate the timeline from initial discovery to clinical trials to about five years.”
Nature Cancer is a journal which covers the latest, most significant cancer-related advances across the life, physical, applied and social sciences, focusing on new approaches for the development and delivery of diagnostics and therapeutics, as well as clinical studies regarding cancer diagnosis, treatment and prevention.
Read the full paper here: https://go.nature.com/3LhuAAy
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. The company is the only preclinical CRO to hold a commercial license to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has nine facilities in the US, Europe and Asia. Find out more: https://www.crownbio.com .
About HUB
HUB Organoids (HUB) is the global leader in the field of adult stem cell-derived organoid. The technology invented by HUB’s scientists in the lab of world-renowned Prof. Hans Clevers represents a paradigm shift for drug discovery and development, preclinical patient stratification, predictive diagnostics, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics. HUB offers licenses to its proprietary technology and provides drug screening services and access to its living organoid biobanks.
About SupresStem
The SuppresSTEM consortium was funded by EU FP7 and involved collaborative work by companies including OcellO B.V./Crown Bioscience, HUB Organoids, and Merus N.V., and international research institutions including the Hubrecht Institute, IRB Barcelona and the Sanger Institute. The Vall d'Hebron Institute of Oncology (VHIO), the Catalan Institute of Oncology and the company Xenopad also collaborated in data for this publication. The consortium set out to develop novel antibody-based therapeutics targeting cancer stem cells for the treatment of colorectal cancer as well as patient-derived organoid-based screening tools to aid drug discovery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428006002/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Estée Lauder Companies Makes Strategic Minority Investment in Mexican Luxury Fragrance Brand XINÚ13.11.2025 22:50:00 CET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced a minority investment in XINÚ, a Mexican luxury fragrance brand inspired by the abundance and exoticism of the American continent. This investment marks the first time The Estée Lauder Companies has invested in a Latin American brand, underscoring the company’s commitment to championing local entrepreneurship and innovation. Since its founding in 2017, XINÚ has created a distinctive universe where fragrance, design, and storytelling converge. The brand is celebrated for its sensorial retail spaces, sustainable design ethos, and products that honor heritage while reimagining modern luxury. “Fragrance excellence and craftsmanship are at the heart of The Estée Lauder Companies, and they drive our passion for discovering new voices in beauty,” said Stéphane de La Faverie, President and Chief Executive Officer, The Estée Lauder Companies. “Mexico has become a vibrant hub of fragrance innovation — a place where craftsmanship and cult
Stage Set for World’s Largest Autonomous Race as A2RL Reaches Full Fan Capacity at Yas Marina Circuit13.11.2025 19:02:00 CET | Press release
15 November at Abu Dhabi’s iconic Yas Marina Circuit, in front of a full capacity crowd Eleven global teams compete for $2.25 million prize World first: Six fully autonomous cars racing head-to-head Human vs. AI showdown featuring former F1 driver Daniil Kvyat against TUM Race will be broadcast globally, this Sunday, 16th November at 3pm GST, on the Abu Dhabi Media Network, StarzPlay, Motorsport TV and the official A2RL YouTube Channel The world’s largest autonomous car race will take place in Abu Dhabi on the 15th of November, as 11 teams from across the globe compete at the frontier of robotics, autonomy and AI for a US$2.25 million prize pool. A2RL Season 2 has been 18 months in the making, with the six fastest teams making it through the tough qualification process to the Grand Final. Ticket allocation for the Yas Marina Circuit event has once again reached full capacity of the main grandstand, as motorsport and technology enthusiasts excitedly prepare to witness an AI competition
TRU Simulation announces delivery and acceptance of the Bell 505 Flight Training Device to Royal Jordanian Air Force13.11.2025 16:00:00 CET | Press release
TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Bell Textron Inc. today announced delivery and acceptance of the Bell 505 Flight Training Device (FTD) to the Royal Jordanian Air Force (RJAF). The purchase agreement with the RJAF includes aircraft delivery complete with a flight training device and a comprehensive computer-based training package to support basic and advanced rotorcraft flight training at the King Hussein Air College in Mafraq, Jordan. This milestone follows the recent delivery of 10 Bell 505 helicopters to the RJAF. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113604706/en/ TRU Simulation + Training announced delivery and acceptance of the Bell 505 Flight Training Device (FTD) to the Royal Jordanian Air Force (RJAF). “The Bell 505 Flight Training Device provides the Royal Jordanian Air Force a highly advanced training solution that enhances pilot readiness through r
TOURISE Destination Initiative Calls for Global Action for Urban Tourism Safety Through AI13.11.2025 15:42:00 CET | Press release
Launched today at the TOURISE Summit, the TOURISE Destination Initiative (TDI) brings together global leaders from government, international organizations, academia, and the private sector, to transform destinations into living laboratories for tourism innovation. Guided by its Declaration of Principles, TDI champions safety, environmental stewardship, cultural preservation, and community-centered development through responsible technology and multi-sector collaboration. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113796086/en/ His Excellency Ahmed Al Khateeb, Saudi Arabia's Minister of Tourism and Chairman of TOURISE, launches the TOURISE Destination Initiative, a global coalition to shape the future of tourism through a destination-centric approach, with co-chairs H.R.H. Prince Turki bin Talal bin Abdulaziz Al Saud, Governor of Aseer Province, and Luigi Brugnaro, Mayor of Venice. They are joined with the TDI founding
Twilio’s Latest Report Highlights Conversational AI’s Rapid Adoption, Challenges, and Perception Gaps13.11.2025 15:00:00 CET | Press release
Survey data shows a 31-point satisfaction gap between business leaders’ beliefs and consumers’ experiences with conversational AIWithin the next year, 59% of organizations expect to fully replace the conversational AI solution they have in place todayMore than 70% of consumers claim they can identify an AI agent, but 90% failed to do so correctly Twilio (NYSE: TWLO), the customer engagement platform that drives real-time, personalized experiences for today’s leading brands, today released its Inside the Conversational AI Revolution report.1 Based on a global survey of 457 business leaders and 4,800 consumers across 15 countries, the report unearths major trends related to conversational AI’s adoption, perceptions, and expectations, including a finding that 99% of organizations anticipate their conversational AI strategy will change in the next 12 months. “Businesses that want to successfully deploy conversational AI for customer service, sales, and marketing need to prioritize customer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom